High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: Final results of a multicenter phase II trial

Journal of Clinical Oncology

Volumn 33, Issue 33, 2015, Pages 3903-3910

  Ferreri, Andrés J M ^a   Donadoni, Giovanni ^a   Cabras, Maria Giuseppina ^c   Patti, Caterina ^d   Mian, Michael ^e   Zambello, Renato ^f   Tarella, Corrado ^g   Di Nicola, Massimo ^b   D'Arco, Alfonso M ^h   Doa, Gianluca ⁱ   Bruno Ventre, Marta ^a   Assanelli, Andrea ^a   Foppoli, Marco ^a   Citterio, Giovanni ^a   Fanni, Alessandro ^c   Mulè, Antonino ^d   Caligaris Cappio, Federico ^a   Ciceri, Fabio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Ospedale Oncologico A Businco   (Italy)

^d VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^e Ospedale di Bolzano   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h Polo Oncologico Nocera Pagani   (Italy)

ⁱ Presidio Ospedaliero S Francesco   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; THIOTEPA; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; HEALTH STATUS; HUMAN; HYPERGLYCEMIA; INJECTION SITE INFECTION; LIVER TOXICITY; MALE; MENINX DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SYSTEMIC DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADOLESCENT; AUTOTRANSPLANTATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; FOLLOW UP; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROCEDURES; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84948458088     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.1236     Document Type: Article

References (22)

1. Haioun C, Besson C, Lepage E., et al: Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients - Groupe D'etudes des Lymphomes de L'adulte. Ann Oncol 11:685-690, 2000
2. Ferreri AJ, Assanelli A, Crocchiolo R., et al: Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: Incidence, risk factors and therapeutic options. Hematol Oncol 27: 61-70, 2009
3. Ferreri AJ: Risk of CNS dissemination in extranodal lymphomas. Lancet Oncol 15:e159-e169, 2014
4. Ferreri AJ, Bruno-Ventre M, Donadoni G., et al: Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol 168:654-662, 2015
5. Bromberg JE, Doorduijn JK, Illerhaus G, et al: Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation: An International Primary Central Nervous System Lymphoma Study Group project. Haematologica 98:808-813, 2013
6. Hollender A, Kvaloy S, Lote K., et al: Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement: A single centre analysis. Eur J Cancer 36:1762-1768, 2000
7. van Besien K., Ha CS, Murphy S, et al: Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91:1178-1184, 1998
8. Williams CD, Pearce R, Taghipour G., et al: Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: Those transplanted with active CNS disease have a poor outcome - A report by the European Bone Marrow Transplant lymphoma registry. J Clin Oncol 12:2415-2422, 1994
9. Kasamon YL, Jones RJ, Piantadosi S, et al: High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant 11:93-100, 2005
10. Korfel A, Elter T, Thiel E., et al: Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica 98:364-370, 2013
11. Doorduijn JK, van Imhoff GW, van Montfort CAGM, et al: Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high dose methotrexate and R-DHAP, followed by autologous stem cell transplantation: A phase II HOVON study. Blood 120:306, 2012 (abstr)
12. Ferreri AJ, Reni M, Foppoli M., et al: High-dose cytarabine plus high-dose methotrexate versus highdose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial. Lancet 374:1512-1520, 2009
13. Ferreri AJ, Ciceri F, Brandes A.A., et al: MATILDE chemotherapy regimen for primary CNS lymphoma: Results at a median follow-up of 12 years. Neurology 82:1370-1373, 2014
14. Tarella C, Zanni M, Magni M., et al: Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: A multicenter Gruppo Italiano Terapie Innnovative nei Linfomi survey. J Clin Oncol 26:3166-3175, 2008
15. Cheson BD, Pfistner B, Juweid M.E., et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
16. Swerdlow SH, Campo E, Harris N.L., et al: WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2008
17. Yule SM, Price L, Pearson A.D., et al: Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin Cancer Res 3:1985-1992, 1997
18. Nicolao P, Giometto B: Neurological toxicity of ifosfamide. Oncology 65:11-16, 2003 (suppl 2)
19. Motl S, Zhuang Y, Waters C.M., et al: Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet 45:871-903, 2006
20. Mappa S, Marturano E, Licata G., et al: Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to highdose methotrexate-based chemotherapy. Hematol Oncol 31:143-150, 2012
21. Takasu S, Wakabayashi T, Kajita Y., et al: Effectiveness of DeVIC chemotherapy for recurrent primary central nervous system lymphoma. No Shinkei Geka 28:789-794, 2000
22. Gisselbrecht C, Glass B, Mounier N., et al: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184-4190, 2010